Actively Recruiting
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
Led by SOLTI Breast Cancer Research Group · Updated on 2025-05-28
300
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
S
SOLTI Breast Cancer Research Group
Lead Sponsor
R
Roche Farma, S.A
Collaborating Sponsor
AI-Summary
What this Trial Is About
HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic breast cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease and expectations, and to provide a blood sample and an archival tumor biopsy. In HOPE Focus these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will enumerate future therapeutic options that match patient history and his genomic profile, when feasible. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years. The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic breast cancer patients.
CONDITIONS
Official Title
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female or male patients residing in Spain
- Age 18 years or older
- Signed informed consent before any study procedures (except registration)
- Self-reported ECOG performance status of 0 or 1
- Diagnosed with metastatic breast cancer either recently diagnosed ER+/HER2- recurrence before metastatic treatment or progressed after at least one metastatic treatment line
You will not qualify if you...
- Any condition that could compromise patient safety or data quality
- Inability or refusal to follow study procedures at inclusion
- More than 3 prior systemic chemotherapy or antibody-drug conjugate treatments for metastatic disease (excluding bone metastases treatments, targeted therapies, or hormonal therapy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
SOLTI Cancer Research Group
Barcelona, Barcelona, Spain, 08008
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here